Seth J. Karp

Seth J. Karp

Auto-generated profile, based on publicly available information

Seth J. Karp

Section of Surgical Sciences, Vanderbilt University Medical Center, Nashville, TN, USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 January 2025 in Science
Verified
Journal Article
Closed access
LOLuisina Ongaro
Luisina Ongaro
XZXiang Zhou
Xiang Zhou
YWYing Wang
Ying Wang
HSHailey Schultz
Hailey Schultz
ZZZiyue Zhou
Ziyue Zhou
DBDaniel J. Bernard
Daniel J. Bernard
Myostatin is a paracrine myokine that regulates muscle mass in a variety of species, including humans. In this work, we report a functional role for myostatin as an endocrine hormone that directly promotes pituitary follicle-stimulating hormone (FSH) synthesis and thereby ovarian function in mice. Previously, this FSH-stimulating role was attributed to other members of the transforming growth factor–β family, the activins. Our results both challenge activin’s eponymous role in FSH synthesis and establish an unexpected endocrine axis between skeletal muscle and the pituitary gland. Our data also suggest that efforts to antagonize myostatin to increase muscle mass may have unintended consequences on fertility.

18 January 2022 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
AWAnji E. Wall
Anji E. Wall
AFAmy Fiedler
Amy Fiedler
SKSeth Karp
Seth Karp
ASAshish Shah
Ashish Shah
GTGiuliano Testa
Giuliano Testa
The novel approach of thoracic normothermic regional perfusion (TA-NRP) for in-situ preservation of organs prior to removal presents a new series of ethical questions about donation after circulatory determination of death (DCD) procedures. This manuscript describes the framework used for the analysis of ethical acceptability of DCD donation and analyzes the specific practice of TA-NRP DCD within that framework to demonstrate that TA-NRP DCD can be performed within the ethical boundaries of DCD donation. We argue that TA-NRP DCD organ procurements meet the ethical standards of informed consent, non-maleficence, adherence to the dead donor rule, and irreversibility, and as such, are ethically acceptable. We also describe the potential benefits of TA-NRP DCD procedures that result from higher organ yields and better recipient outcomes. Finally, we call for open and transparent support of TA-NRP DCD by professional organizations as a necessary cornerstone for the advancement of TA-NRP DCD procedures.

31 May 2010 in Journal of Experimental Medicine
Verified
Journal Article
Open access
KHKaren Ho
Karen Ho
NDNhue L. Do
Nhue L. Do
Hasan OtuHasan Otu
Hasan Otu
MDMartin J. Dib
Martin J. Dib
XRXianghui Ren
Xianghui Ren
SKSeth J. Karp
Seth J. Karp
How proliferative and inhibitory signals integrate to control liver regeneration remains poorly understood. A screen for antiproliferative factors repressed after liver injury identified transducer of ErbB2.1 (Tob1), a member of the PC3/BTG1 family of mito-inhibitory molecules as a target for further evaluation. Tob1 protein decreases after 2/3 hepatectomy in mice secondary to posttranscriptional mechanisms. Deletion of Tob1 increases hepatocyte proliferation and accelerates restoration of liver mass after hepatectomy. Down-regulation of Tob1 is required for normal liver regeneration, and Tob1 controls hepatocyte proliferation in a dose-dependent fashion. Tob1 associates directly with both Caf1 and cyclin-dependent kinase (Cdk) 1 and modulates Cdk1 kinase activity. In addition, Tob1 has significant effects on the transcription of critical cell cycle components, including E2F target genes and genes involved in p53 signaling. We provide direct evidence that levels of an inhibitory factor control the rate of liver regeneration, and we identify Tob1 as a crucial check point molecule that modulates the expression and activity of cell cycle proteins.

22 May 2022 in Cancers
Verified
Journal Article
Open access
PDF file
RMRyota Masuzaki
Ryota Masuzaki
Tatsuo KandaTatsuo Kanda
Tatsuo Kanda
RSReina Sasaki-Tanaka
Reina Sasaki-Tanaka
NMNaoki Matsumoto
Naoki Matsumoto
Kazushige NireiKazushige Nirei
Kazushige Nirei
Hirofumi KogureHirofumi Kogure
Hirofumi Kogure
Cytokines are secreted soluble glycoproteins that regulate cellular growth, proliferation, and differentiation. Suppressors of cytokine signaling (SOCS) proteins negatively regulate cytokine signaling and form a classical negative feedback loop in the signaling pathways. There are eight members of the SOCS family. The SOCS proteins are all comprised of a loosely conserved N-terminal domain, a central Src homology 2 (SH2) domain, and a highly conserved SOCS box at the C-terminus. The role of SOCS proteins has been implicated in the regulation of cytokines and growth factors in liver diseases. The SOCS1 and SOCS3 proteins are involved in immune response and inhibit protective interferon signaling in viral hepatitis. A decreased expression of SOCS3 is associated with advanced stage and poor prognosis of patients with hepatocellular carcinoma (HCC). DNA methylations of SOCS1 and SOCS3 are found in HCC. Precise regulation of liver regeneration is influenced by stimulatory and inhibitory factors after partial hepatectomy (PH), in particular, SOCS2 and SOCS3 are induced at an early time point after PH. Evidence supporting the important role of SOCS signaling during liver regeneration also supports a role of SOCS signaling in HCC. Immuno-oncology drugs are now the first-line therapy for advanced HCC. The SOCS can be potential targets for HCC in terms of cell proliferation, cell differentiation, and immune response. In this literature review, we summarize recent findings of the SOCS family proteins related to HCC and liver diseases.

4 November 2020 in The American Journal of Pathology
Verified
Journal Article
Closed access
RMRyota Masuzaki
Ryota Masuzaki
KRKevin C. Ray
Kevin C. Ray
JRJoseph Roland
Joseph Roland
RZRoy Zent
Roy Zent
YLYoungmin A. Lee
Youngmin A. Lee
SKSeth J. Karp
Seth J. Karp

12 September 2021 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
RLRaymond J. Lynch
Raymond J. Lynch
BDBrianna L. Doby
Brianna L. Doby
DGDavid S. Goldberg
David S. Goldberg
KLKevin J. Lee
Kevin J. Lee
ACArielle Cimeno
Arielle Cimeno
SKSeth J. Karp
Seth J. Karp
To meet new Centers for Medicare & Medicaid Services (CMS) metrics, organ procurement organizations (OPOs) will benefit from understanding performance across decedent and hospital types. We sought to determine the utility of existing data reporting structures for this purpose by reviewing Scientific Registry of Transplant Recipient (SRTR) OPO-Specific Reports (OSRs) from 2013-2019. OSRs contain both the Standardized Donation Rate Ratio (SDRR) metric and OPO-reported numbers of ‘eligible deaths’ and donors by hospital. Donor hospitals were characterized using information from Homeland Infrastructure Foundation-Level Data, Dartmouth Atlas Hospital Service Area, and US Census Bureau. Hospital data reported by OPOs showed 51% higher eligible death donors and 140% higher non-eligible death donors per 100 hundred inpatient beds in CMS ranked top vs. bottom OPO quartiles. Top quartile OPOs by the CMS metric recovered 78% more donors than those in the bottom quartile, but were indistinguishable by SDRR rankings. These differences persisted across hospital sizes, trauma case mix, and area demographics. OPOs with divergent performance were indistinguishable over time by SDRR, but showed changes to hospital level recovery patterns in SRTR data. Contemporaneous recognition of underperformance across hospitals may provide important and actionable data for regulators and OPOs for focused quality improvement projects.